Tesamorelin has the rigorous Phase III data, the FDA approval for adult use, the documented 15 percent visceral fat reduction, and the favorable metabolic profile that comes with that fat loss
Additionally, it promotes smooth communication with payers to accelerate reimbursement and alleviate administrative burdens for joint aspiration and injection procedures
Selectivity Advantage: Unlike GHRP-2 and GHRP-6, which non-selectively activate multiple pituitary hormone pathways (ACTH, cortisol, prolactin), ipamorelin demonstrates minimal cross-reactivity with non-target pituitary receptors, making it pharmacologically similar to GHRH in its hormone-releasing selectivity
A: Amylin and GLP-1 receptors are in overlapping but distinct brain regions
Separate sites reduce the risk of local irritation and make it easier to identify the source of any injection site reactions